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BK virus infection and outcome 
following kidney transplantation 
in childhood
James McCaffrey1*, Vijesh J. Bhute2 & Mohan Shenoy3
BK virus associated nephropathy (BKN) is an important cause of kidney allograft failure. In a cohort of 
paediatric kidney transplant recipients, we aimed to understand the incidence and clinical outcome 
associated with BKN, as well as identify risk factors for BKN and BK viraemia development. We 
retrospectively analysed all patients who received a kidney transplant and received follow up care in 
our centre between 2009–2019. Among 106 patients included in the study (mean follow up 4.5 years), 
32/106 (30.2%) patients experienced BK viraemia. The incidence of BKN was 7/106 (6.6%). The median 
time of BK viraemia development post-transplant was 279.5 days compared to 90.0 days for BKN. 
Development of BKN was associated with younger age at transplantation (p = 0.013). Development 
of BK viraemia was associated with negative recipient serology for cytomegalovirus (CMV) at time 
of transplantation (p = 0.012) and a higher net level of immunosuppression (p = 0.039). There was 
no difference in graft function at latest follow up between those who experienced BKN and those 
without BKN. This study demonstrates that BK virus infection is associated with younger age at 
transplantation, CMV negative recipient serostatus and higher levels of immunosuppression. Judicious 
monitoring of BK viraemia in paediatric transplant recipients, coupled with timely clinical intervention 
can result in similar long-term outcomes for BKN patients compared to controls.
BK virus (BKPyV) is a member of the Polyomaviridae family of double-stranded DNA  viruses1. Primary 
BKPyV infection is mainly asymptomatic and occurs predominantly before adolescence, with an IgG seropreva-
lence > 90% in 5–9 year old healthy children. Seroprevalence rates in later life demonstrate an age-dependent 
decline with 68% of 60–69 year olds showing IgG  positivity2. Peripheral blood mononuclear cells disseminate 
BKPyV to the urinary tract where the virus establishes a persistent non-replicative latent phase in renal tubular 
epithelial cells and  urothelium3,4. Periodic BKPyV reactivation occurs, with asymptomatic urinary shedding 
seen in 7% of healthy  adults5.
In kidney allograft recipients, active replication of BKPyV can lead to BKPyV-associated nephropathy (BKN) 
and subsequent graft dysfunction and premature  loss6. The emergence of BKN in the last decade of the twentieth 
century coincided with the introduction of potent immunosuppressive agents such as tacrolimus and mycophe-
nolate mofetil (MMF), leading to the proposal that a higher level of immunosuppression is a risk factor for the 
development of  BKN7,8. BKPyV viraemia precedes the onset of BKN, and polymerase-chain-reaction (PCR) 
assays of plasma are a specific and sensitive method to detect early  nephropathy9. Before recognition of the 
necessity to identify and treat BKN in a timely manner, graft loss rates as high as 67% were documented in the 
adult  population10.
Anti-viral agents have demonstrated minimal or no efficacy in clearing  BKPyV11–13, and treatment involves 
reducing immunosuppressive therapy to restore the capability of the host immune system to control BKPyV 
replication and prevent progression to  BKN14. Levels of BKPyV-specific IgG antibodies and T-cells increase fol-
lowing a reduction in immunosuppression and peak at the time of BKPyV viraemia  resolution15.
In the paediatric kidney transplant population, rates of BKPyV viraemia range from 18–37% and BKN is 
identified in 0–16% of  patients8,15–23. In a case series of 32 patients under the age of 20 years with BKN, 3 (9%) 
of allografts were  lost6. Reported risk factors for the development of BKN in the paediatric population include 
allograft recipient BKPyV seronegativity at time of  transplantation20,23, zero human leukocyte antigens (HLA) 
-A and -DR mismatches between transplant donor and  recipient22, increased levels of immunosuppression,8,21 
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younger age of recipient at  transplantation21, and a tacrolimus- compared to ciclosporin- based immunosup-
pression  regimen21. A recent study in adult kidney transplant recipients suggested prophylactic use of the anti-
cytomegalovirus (CMV) agent valganciclovir may be associated with an increased risk of  BKN24.
In this single-centre study, we report our experience of BKN in a paediatric transplant recipient population 
over a 10-year period, with patients predominantly receiving a steroid-sparing immunosuppressive  regimen25. 
Specific aims of the study were to: (1) evaluate rates of BKPyV viraemia and BVN in this population; (2) under-
stand the morbidity associated with BKPyV viraemia and BKN; and (3) identify risk factors for the development 
of BKPyV viraemia and BKN.
Results
Study population. A total of 106 patients met the requirements for inclusion in the study, with a mean 
follow up time of 54.3 months. There were 7 graft failures (mean time in months post-transplant: 44.0 months, 
range 18–70  months) and 2 deaths (see Supplementary Table  S1). There were no graft losses or deaths in 
 BKNHi/B+ patients (Table 1). 99/106 patients received the steroid-sparing TWIST immunosuppressive regimen. 
7/106 patients received a non-TWIST immunosuppression regimen (reasons including enrolment in research 
trials and transplant occurring before TWIST became standard local protocol). Characteristics for the whole 
cohort are provided in Supplementary Tables S2, S3 and S4.
Incidence of BKN. There were 41 episodes of BK viraemia in 32/106 patients (30.2%). 2/106 patients (1.9%) 
experienced an episode of  BKNB+, and a further 5/106 (4.7%) patients experienced an episode of  BKNHi. There-
fore, the incidence of  BKNHi/B+ was 7/106 (6.6%). 25/106 patients (23.6%) experienced an episode of  BKNLow 
without an episode of  BKNHi/B+ at any point post-transplantation.
Timing of episodes. The mean (median) time of viraemia onset post-transplant in the 34 episodes of 
 BKNLow was 508.4 (279.5) days compared to 234.3 (90.0) days for  BKNHi/B+ (p = 0.199) (Fig. 1a and Supplemen-
tary Table S5). The range of time of onset of viraemia post-transplant was 19–1775 days for  BKNLow episodes and 
33–656 days for  BKNHi/B+. 23.5% of  BKNLow episodes occurred more than 2 years post transplant. In contrast, all 
episodes of  BKNHi/B+ occurred within the first 2 years following transplantation.
12/34 (35.3%) of total  BKNLow episodes occurred in the 6 months immediately post-transplant compared to 
5/7 (71.4%) episodes of  BKNHi/B+. A plot of the Kaplan–Meier estimator demonstrated no significant difference 
between the timing of onset of  BKNLow and  BKNHi/B+ viraemia (Fig. 1b). An overview of the temporal distribu-
tion of BK viraemia episodes is provided in Fig. 2.
No difference between length of viraemia per episode was noted between  BKVAll subgroups (mean 105.8 days 
for  BKNLow compared to 104.0 days for  BKNHi/B+, p = 0.265) (Fig. 1c and Supplementary Table S6).
Analysis of risk factors. Univariate analysis was performed to assess potential risk factors for the devel-
opment of BKPyV viraemia and BKN. Age at transplant was significantly different between the 3 groups 
(p = 0.0369) (Table 1). Bonferroni’s post-test was used to compare groups and there was a significant difference 
in age at transplantation between no-BKV patients (mean 11.2 years) compared to  BKNHi/B+ patients (mean 
6.2 years) (p = 0.013, adjusted critical value αBonferroni = 0.0167 for three group comparison). There was no differ-
ence between age at transplantation between no-BKV patients and  BKNLow patients (mean 10.2 years) (p = 0.363).
CMV serology status of allograft recipients was also significantly different between the groups (p = 0.012) 
(Table 2).  BKNLow patients were less likely to have recorded positive CMV serology at time of transplantation 
Table 1.  Univariate analysis of patient cohort characteristics. + Data not available for six patients. 
BPAR = biopsy proven acute rejection.
Characteristic
No-BKV (n = 74) BKNLow (n = 25) BKNHi/B+ (n = 7)
p valueProportion (%) Mean Proportion (%) Mean Proportion (%) Mean
Female 24/74 (32.4%) 9/25 (36.0%) 2/7 (28.6%)
0.939
Male 50/74 (67.6%) 16/25 (64.0%) 5/7 (71.4%)
Age at transplant (years) 11.2 10.2 6.2 0.0369
Ethnicity: White  British+ 45/68 (66.2%) 17/25 (68.0%) 5/7 (71.4%) 1.000
Living transplant donor 43/74 (58.1%) 18/25 (72.0%) 6/7 (85.7%) 0.228
Cold ischaemia time (minutes) 345.2 235.6 143.9 0.218
Steroid-free regimen at latest follow up 44/74 (59.5%) 11/25 (44.0%) 4/7 (57.1%) 0.448
MMF part of regimen at latest follow up 55/74 (74.3%) 16/25 (64.0%) 5/7 (71.4%) 0.543
Exposure to anti-CMV therapy 24/74 (32.4) 10/25 (40.0%) 3/7 (42.9%) 0.735
BPAR 21/74 (28.4) 6/25 (24.0%) 2/7 (28.6%) 0.933
Graft failure 7/74 (9.5%) 1/25 (4.0%) 0/7 (0.0%) 0.802
Death 2/74 (2.7%) 0/25 (0.0%) 0/7 (0.0%) 1.000
Length of follow up (months) 55.8 48.0 60.1 0.453
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Figure 1.  Characteristics of BKyPV viraemia episodes. (a) Time of onset of viraemia episodes post-transplant 
(p = 0.199, Mann–Whitney U test). Red line indicates mean value for each group. (b) Cumulative risk of 
developing BKPyV viraemia over time (curves compared using log-rank / Mantel-Cox test). (c) Violin plot 
comparing length of viraemia episodes between groups (p = 0.265, Mann–Whitney U test). Quartiles are plotted 
with median value in red. ns = not significant.
Figure 2.  Incidence of  BKNLow,  BKNB+ and  BKNHi in years 1–5 post transplantation.






Proportion (%) p value
CMV status donor
 + 29/74 (39.2%) 11/25 (44.0%) 3/7 (42.9%)
0.944
 − 45/74 (60.8%) 14/25 (56.0%) 4/7 (57.1%)
CMV status recipient
 + 27/74 (36.5%) 2/25 (8.0%) 3/7 (42.9%)
0.012
 − 47/74 (63.5%) 23/25 (92.0%) 4/7 (57.1%)
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(2/25, 8.0%) than no-BKV (27/74. 36.5%) and  BKNHi/B+ (3/7, 42.9%) patients. There was no difference in exposure 
to anti-CMV therapy between patient sub-groups (Table 1 and Supplementary Table S7).
No differences between patient subgroups were identified for the following characteristics: sex, cold ischaemia 
time, ethnic background, frequency of BPAR, use of steroids/MMF, source of graft donor (living/cadaveric) and 
HLA mismatch status (Table 1 and Supplementary Table S8).
Multinomial logistic analysis confirmed the univariate analysis findings of CMV recipient serostatus and age 
at time of transplant being independently predictive of BKN and BKPyV viraemia. Additionally, age and CMV 
serostatus in the same model are predictive of BKN/ BKPyV viraemia (p = 0.002) (Table 3).
Immunosuppression. All (7/7) episodes of  BKNHi/B+ elicited a reduction in immunosuppression by the 
treating clinician compared to 13/34 (38.2%) of episodes of  BKNLow (Supplementary Table S9). However, when 
the decision to reduce immunosuppression was made, there was no significant difference between the size of 
reduction between  BKNLow (mean reduction in paediatric Vasudev score − 23.0%) and  BKNHi/B+ (mean reduc-
tion in paediatric Vasudev score -22.2%) (Fig. 3a,b).
To understand how the total level of immunosuppression varied for patients across their post-transplant 
clinical course, a paediatric Vasudev score was calculated for all patients at latest follow up and, for relevant 
patients, at time of BKPyV viraemia onset. Additionally we quantified the level of immunosuppression for 
Table 3.  Multinomial Logistic Regression Analysis. a Log Likelihood tests ; bOR: odds ratio; cCI: confidence 
interval for odds ratio; dReference category is No-BKV.
Factor
p value of reduced 
 modela
p value of final 
model
BKNLow  statusd BKNHi/B+  statusd
ORb 95%  CIc p value ORb 95%  CIc p value
Age at transplant 0.027
0.002
0.975 0.889 to 1.070 0.594 0.785 0.636 to 0.968 0.024
CMV serostatus of 
recipient 0.009 0.157 0.034 to 0.723 0.018 1.869 0.350 to 9.968 0.464
Figure 3.  Change in net immunosuppression over time. (a) Percentage change in paediatric 
immunosuppression Vasudev score during episodes of BKPyV viraemia (p = 0.588, Mann–Whitney U test). 
(b) Absolute change in paediatric immunosuppression Vasudev score during episodes of BKPyV viraemia 
(p > 0.999, Mann–Whitney U test). c Mean paediatric Vasudev immunosuppression score at latest follow up, at 
BKPyV viraemia diagnosis and at 462 days post-transplantation in no-BKV group. Groups compared using one 
way ANOVA followed by Tukey’s test. ns = not significant (p = 0.996), ***p = 0.0115, **p = 0.0390, *p = 0.0391.
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no-BKV patients at the mean time  BKVAll patients developed viraemia post-transplant (462 days). This allowed 
us to analyse no-BKV and  BKVAll patients at comparable points in their clinical course.
There was no significant difference in paediatric Vasudev score at latest follow up between no-BKV patients 
(mean 4.4 units) compared to  BKVAll patients (mean 4.7 units) (Fig. 3c). However, the level of immunosup-
pression was significantly higher for  BKVAll patients at time of BKPyV viraemia diagnosis (mean 6.5 units) 
compared to latest follow-up (p = 0.012). Furthermore, immunosuppression level in no-BKV patients at 462 days 
post-transplantation (mean 5.2 units) was significantly lower than for  BKVAll patients at BKPyV viraemia diag-
nosis (p = 0.0390). This shows that patients who developed BKPyV viraemia were exposed to a higher level of 
immunosuppression at time of diagnosis than patients without BKPyV viraemia.
To understand if increases in immunosuppression following an episode of acute rejection may explain the 
higher paediatric Vasudev score recorded for  BKVAll patients, we examined whether BKPyV viraemia or acute 
rejection occurred first for each relevant patient. There were 8 episodes of BPAR among  BKVAll patients: in 
4/8 episodes rejection occurred before BKPyV viraemia and in 4/8 episodes BKPyV viraemia occurred before 
rejection. 2/2  BKNB+ patients experienced an episode of acute rejection: in both instances BKN occurred before 
acute rejection.
Effect on kidney function. There was no significant difference in eCrCl between patient sub-groups at lat-
est follow up or significant difference in the eCrCl percentage change from baseline to latest follow up between 
patient sub-groups (Fig. 4a,b).
To analyse changes in kidney function during periods of viraemia, the eCrCl at BKPyV viraemia diagnosis was 
compared to the lowest eCrCl during the period of viraemia for each patient and a percentage change was cal-
culated.  BKNLow patients showed a mean eCrCl change of − 0.2%, while  BKNHi/B+ patients showed a mean eCrCl 
change of − 10.0% (Fig. 4c). However, there was no significant difference between the eCrCl at BKPyV viraemia 
diagnosis and the average eCrCl reading during viraemia for either  BKNLow or  BKNHi/B+ patients (Supplementary 
Figure S1). A representative plot of plasma viral load and eCrCl of a patient with  BKNHi is shown in Fig. 4d.
Discussion
The salient findings of this study involving 106 paediatric kidney transplant recipients are as follows: (1) 2/106 
individuals experienced  BKNB+ and 5/106 patients developed  BKNHi, giving an overall BKN incidence of 7/106 
(6.6%); (2) 30.2% patients experienced BKPyV viraemia; (3) the incidences of  BKNLow,  BKNB+ and  BKNHi were 
highest during the first year post-transplant; (4) 23.5% of  BKNLow episodes occurred after 2 years post-transplan-
tation; (5) there was no significant difference in long-term graft function between patients experiencing BKPyV 
Figure 4.  Effect of BKPyV viraemia on graft function. (a) Estimated creatinine clearance (eCrCl) at 
baseline, latest follow up and at BKPyV viraemia diagnosis. Black bars = ‘No-BKV’, green bars = ‘BKNLow’, red 
bars = ‘BKNHi/B+’. [ns (1) p = 0.996, ns (2) p = 0.998, one way ANOVA followed by Tukey’s test]. (b) Percentage 
change in eCrCl at latest follow up compared to baseline. (c) Percentage change in lowest eCrCl recorded during 
BKPyV viraemia compared to eCrCl at BKPyV viraemia diagnosis (ns p = 0.109, Mann–Whitney U test). (d) 
Representative plot showing plasma viral load and eCrCl of a patient with  BKNHi over time. Green arrows 
indicate points at which immunosuppressive therapy was reduced.
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viraemia/BKN and no-BK controls; (6) younger age at transplantation, CMV negative serology of the allograft 
recipient at time of transplantation, and a higher level of immunosuppression were associated with an increased 
risk of BKN/ BKPyV viraemia development.
Our incidence of  BKNB+ (1.9%) is slightly lower than rates of 3.5–4.5% recorded in previous  studies20–22. We 
found similar levels of BKPyV viraemia to a recent European mulitcentre study (30.2% vs. 36.7%), but lower 
level of  BKNHi (4.7% vs. 15.8%)21. There were no graft losses from  BKNHi/B+ patients in our cohort, whereas graft 
failure rates of 7.1–24.0% have previously been recorded in American and European  data21,22.
There was no difference in eCrCl at final follow up between patients experiencing BKPyV viraemia or BKN 
and patients without BKPyV viraemia / BKN. Our graft outcome findings are similar to a prospective study of 
62 paediatric transplants which reported no difference in SCr between patients who developed BKPyV viraemia 
and those who did not (36 months follow up post-transplantation)15. Data from adult transplant recipients indi-
cated that immunosuppression can safely be reduced in patients with BKPyV viraemia to prevent progression 
to BKN, without a concomitant increase in the incidence of acute  rejection14. However, some paediatric data 
suggested an increased risk of BKPyV viraemia in patients who had experienced an episode of acute  rejection15. 
In the current study, we found no difference in rates of BPAR among patient sub-groups, and in the 8 episodes 
of BPAR occurring in  BKVAll patients, only half preceded BKPyV viraemia development. These observations 
suggest that increases in immunosuppression due to rejection are unlikely to be a major contributor to BKPyV 
viraemia development in our cohort.
Rates of BKPyV viraemia in the current study exceed those found in the adult transplant population 
(11.5–12.8%)14,26, and suggests children may have an increased risk of developing BKPyV-associated pathology. 
Indeed, we identified younger age at transplantation as a risk factor for BKN development. As BKPyV seroposi-
tivity increases from 6% in the 1–4 year age range to 91% in the 5–9 year age  range26, it is likely that a propor-
tion of the BKN episodes in our cohort among the younger children represented primary BKPyV infection. No 
definitive evidence exists demonstrating that primary BKPyV replication in seronegative individuals results in 
a poorer clinical outcome compared to secondary BKPyV replication in seropositive  individuals6. However, 
our finding is in agreement with other  studies21, and suggests younger transplant recipients may benefit from 
increased frequency of monitoring and rapid instigation of treatment to prevent uncontrolled viral replication.
We found that CMV seronegative individuals were more likely to develop BKPyV viraemia than CMV 
seropositive patients. Following a recent report linking prophylactic valganciclovir use with an increased risk 
of  BKN24, we investigated whether anti-CMV therapy (routinely prescribed in CMV negative individuals) was 
associated with an increased risk of BKPyV replication in our cohort. However, we found no evidence to support 
this (Table 1 and Supplementary Table S7). CMV seropositivity rapidly increases with age during childhood in 
a similar manner to rates of BKPyV  seropositivity27. It is therefore possible that seronegative CMV individuals 
are more likely to also be BKPyV seronegative, and therefore at heightened risk of uncontrolled viral replication 
during primary BKPyV infection. However, due to the retrospective nature of the study, this conjecture cannot 
be confirmed.
Our data supports previous observations that a higher level of immunosuppression is a risk factor for BKPyV 
reactivation. A tacrolimus/MMF-based immunosuppression regimen has been shown to double the risk of 
BKPyV viraemia compared to a ciclosporin /MMF-based  regimen21. However, rates of BKPyV viraemia in our 
cohort (predominantly tac/MMF-based regimen) are comparable to those treated with alternative regimens.
Limitations of the current study include the retrospective approach and relatively small number of subjects 
in comparison to multi-centre investigations. In particular, the low numbers of patients experiencing BKN in 
this study reduces the confidence with which definitive conclusions can be drawn from these data. Additionally, 
a prospective approach would have allowed collection of biological samples at various time points throughout a 
patient’s clinical course to interrogate BKPyV serostatus at the time of transplantation and understand the effect 
seronegativity has on clinical outcome.
Overall, our results demonstrate that control of BKPyV replication in paediatric transplant recipients can be 
attained through judicious surveillance and timely reduction in immunosuppression, without an increased risk 
of acute rejection. This approach results in comparable graft function and survival outcomes between patients 
developing BKN and those without evidence of viraemia. The findings that younger age at transplantation sig-
nificantly increases a patient’s risk of developing BKN, and almost a quarter of BKPyV viraemia episodes occur 
later than 2 years post-transplant has implications for the development of BKN surveillance strategies.
Methods
Study design. This is a retrospective cohort analysis of patients receiving a kidney transplant at the Royal 
Manchester Children’s Hospital (RMCH) (UK). Case notes were reviewed from June 2009 to January 2019 and 
patients who met the following requirements were included in the study: (1) Aged < 19 years at time of transplan-
tation; (2) a minimum of 12 months follow-up data; and (3) transplant performed at RMCH. For patients who 
received more than one transplant, the first transplant was evaluated.
Clinical and serological data were collected at time of transplant and at months 1, 3, 6, 9, 12 months post-
transplantation and at 6 monthly intervals thereafter. All plasma BKPyV quantification and histology results 
were recorded. Immunosuppression regimens for each patient were documented at latest follow up, and dur-
ing BKPyV viraemia episodes for relevant patients. Contemporaneous patient height and weight results were 
recorded for each serum creatinine (SCr) reading, to allow the estimated creatinine clearance (eCrCl) to be 
calculated using the standard Schwartz formula (k = 40, as per local protocol)28. All SCr readings during periods 
of BKPyV viraemia were recorded. The study protocol was reviewed by the Clinical Trial Management Depart-
ment (Manchester University NHS Foundation Trust) who waived ethical approval for this study involving 
the retrospective collection of anonymised data. They concluded that informed consent was not required from 
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study participants. The study was performed in accordance with Manchester University NHS Foundation Trust 
guidelines. No patient identifiable data was recorded.
BKPyV surveillance and immunosuppression regimen. Plasma BKPyV monitoring is performed in 
all kidney transplant recipients every month during the first year post-transplantation and on an annual basis 
thereafter using a TaqMan PCR-based approach. Monitoring is performed more frequently at the treating clini-
cian’s discretion.
The standard local immunosuppression approach is the steroid-sparing (TWIST)  protocol25. Briefly, this 
involves induction therapy with the interleukin 2 receptor monoclonal antibody antagonist, basiliximab, on day 
0 and day 4 post transplantation, coupled with a rapidly weaning course of prednisolone which is discontinued 
on day 5. Long-term immunosuppression is provided by tacrolimus and MMF. The net immunosuppressive load 
at different time points for each patient was quantified using the paediatric Vasudev  score29. This score provides 
an estimation of the overall immunosuppressive load by integrating the immunosuppressant types, doses and 
body surface area of each patient. For example, a patient administered 1.2 mg/m2 per day of tacrolimus (equating 
to a paediatric Vasudev score of 1 unit) and 580 mg/m2 per day of MMF (equating to a paediatric Vasudev score 
of 2 units), would have a total paediatric Vasudev score of 3 units.
Definitions. Patients with no recorded positive BKPyV plasma result or histological evidence of BKN were 
designated as ‘no-BKV.’ Patients with any recordable level of BKPyV viraemia at any time during study follow-up 
were designated as ‘BKVAll.’ The  BKVAll group was subdivided into three groups: (1) those with biopsy-proven BKN 
(‘BKNB+’); (2) those with presumptive BKN (‘BKNHi’) without histological evidence of BKN.  BKNHi is defined as 
a sustained (> 3 week) high-level viraemia (> 104 copies/mL), as per international  recommendations21,30; and (3) 
patients with BKPyV viraemia but not meeting the requirements for either  BKNB+ or  BKNHi (‘BKNHi/B+’), were 
designated as having low-level viraemia (‘BKNLow’).
The length of viraemia for each episode was defined as the length of time from the first positive BKPyV 
plasma viraemia result until plasma levels were again undetectable. Baseline eCrCl was defined as the highest 
eCrCl recorded during the first year following transplantation. Graft failure was defined as the requirement to 
return to dialysis after the first week post-transplantation.
Statistical analysis. Univariate analysis of risk factors was performed using Fisher’s exact test and chi-
squared test for correlation (for categorical variables) and one-way analysis of variance (ANOVA) with Bonfer-
roni’s post-hoc test (for quantitative variables). Analysis of clinical outcomes was performed using the non-
parametric Mann–Whitney U test or one-way ANOVA with Tukey’s test, as appropriate.
Multinomial analysis. A multinomial logistic regression analysis was used to predict the BKN develop-
ment. The following variables were considered for the model: gender, ethnicity, age at transplant, cold ischaemia 
time, biopsy-proven acute rejection (BPAR), source of allograft (cadaveric/living), use of steroid-free regimen at 
latest follow-up, use of MMF at latest follow up, exposure to anti-CMV therapy, HLA mismatch, recipient CMV 
status, donor CMV status. The analysis was performed in IBM SPSS Statistics Version 26. A parsimonious model 
was developed by using forward selection method. The final model consisted of one factor: CMV serostatus of 
recipient and one covariate: age at transplant.
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